Cantor Fitzgerald Downgrades CymaBay Therapeutics to Neutral, Announces $32.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska downgraded CymaBay Therapeutics (CBAY) from Overweight to Neutral and set a price target of $32.5. This adjustment reflects a change in the firm's outlook on the stock.
February 13, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald downgraded CymaBay Therapeutics to Neutral and set a price target of $32.5, indicating a change in the stock's outlook.
The downgrade from Overweight to Neutral by a significant analyst firm like Cantor Fitzgerald can have a mixed impact on investor sentiment. While the establishment of a price target suggests a belief in the stock's value potential, the downgrade itself may temper short-term bullish sentiment. The impact is considered neutral as the new price target could offset some negative sentiment from the downgrade.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100